XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout. Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026
We received XORTX Therapeutics Inc. and we are glad to publish the following press release: "XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide an outline of its anticipated…